Inflammation in Dry Eye Disease-Pathogenesis, Preclinical Animal Models, and Treatments

被引:0
作者
Bhujbal, Santosh [1 ]
Rupenthal, Ilva D. [1 ]
Steven, Philipp [2 ,3 ,4 ]
Agarwal, Priyanka [1 ]
机构
[1] Univ Auckland, Buchanan Ocular Therapeut Unit, Dept Ophthalmol, Aotearoa New Zealand Natl Eye Ctr,Fac Med & Hlth S, 85 Pk Rd, Auckland 1142, New Zealand
[2] Univ Cologne, Clin Internal Med 1, Cologne, Germany
[3] Univ Cologne, Fac Med, Dept Ophthalmol, Cologne, Germany
[4] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
关键词
dry eye disease; inflammation; preclinical models; anti-inflammatory therapy; ocular surface; MEIBOMIAN GLAND DYSFUNCTION; OCULAR SURFACE DISEASE; 0.18-PERCENT SODIUM HYALURONATE; OPHTHALMIC SOLUTION 1-PERCENT; INDUCED MOUSE MODEL; CYCLOSPORINE-A; LACRIMAL GLAND; TEAR FILM; SJOGRENS-SYNDROME; KERATOCONJUNCTIVITIS SICCA;
D O I
10.1089/jop.2024.0103
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Dry eye disease (DED) is a rapidly growing ocular surface disease with a significant socioeconomic impact that affects the patients' visual function and, thus, their quality of life. It is distinguished by a loss of tear film homeostasis, leading to tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities, with all of these playing etiological roles in the propagation of the vicious DED circle. While current treatments primarily focus on reducing tear film instability and hyperosmolarity, increasingly more attention is being placed on tackling the underlying inflammation that propagates and potentiates these factors. As such, preclinical models are crucial to further elucidate the DED pathophysiology and develop novel therapeutic strategies. This review outlines the role of inflammation in DED, highlighting related signs and diagnostic tools before focusing on relevant preclinical animal models and potential therapeutic strategies to tackle DED-associated inflammation.
引用
收藏
页码:638 / 658
页数:21
相关论文
共 226 条
  • [1] Formulation Considerations for the Management of Dry Eye Disease
    Agarwal, Priyanka
    Craig, Jennifer P.
    Rupenthal, Ilva D.
    [J]. PHARMACEUTICS, 2021, 13 (02) : 1 - 19
  • [2] Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics
    Agarwal, Priyanka
    Khun, Darina
    Kroesser, Sonja
    Eickhoff, Kirsten
    Wells, Frederick S.
    Willmott, Geoff R.
    Craig, Jennifer P.
    Rupenthal, Ilva D.
    [J]. OCULAR SURFACE, 2019, 17 (02) : 241 - 249
  • [3] Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs
    Agarwal, Priyanka
    Scherer, Dieter
    Guenther, Bernhard
    Rupenthal, Ilva D.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 538 (1-2) : 119 - 129
  • [4] Modern approaches to the ocular delivery of cyclosporine A
    Agarwal, Priyanka
    Rupenthal, Ilva D.
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (06) : 977 - 988
  • [5] Effects of Systane((R)) Balance on noninvasive tear film break-up time in patients with lipid-deficient dry eye
    Aguilar, Alejandro J.
    Marquez, Maria I.
    Albera, Paula A.
    Tredicce, Jorge L.
    Berra, Alejandro
    [J]. CLINICAL OPHTHALMOLOGY, 2014, 8 : 2365 - 2372
  • [6] Differential Diagnosis of Sjogren Versus Non-Sjogren Dry Eye Through Tear Film Biomarkers
    Akpek, Esen K.
    Wu, Henry Y.
    Karakus, Sezen
    Zhang, Qin
    Masli, Sharmila
    [J]. CORNEA, 2020, 39 (08) : 991 - 997
  • [7] Ames Philip, 2015, Clin Investig (Lond), V5, P267, DOI 10.4155/cli.14.135
  • [8] [Anonymous], 2019, SUN PHARMA GLOBAL FZ
  • [9] [Anonymous], About us
  • [10] [Anonymous], 2017, RESTASIS CYCLOSPORIN